Neurophet introduces AI-powered brain imaging analysis technology at AD/PD 2024
SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the international conference on Alzheimer's and Parkinson's diseases and related neurological disorders (AD/PD 2024).
- At this conference, Neurophet will introduce Alzheimer's disease treatment related technologies planned to be commercialized such as analysis of the side effect and amyloid-positive prediction.
- Neurophet AQUA analyzes brain atrophy and white matter hyperintensities (WMH) found in brain MRI of most Alzheimer's disease patients.
- Neurophet SCALE PET provides quantitative regional amyloid beta deposition, known as the causative agent of Alzheimer's disease, using PET images.
- Neurophet plans to launch total solution for Alzheimer's disease treatment including ARIA analysis, since Neurophet has the technology to analyze ARIA.